Navigation Links
Navigenics'(TM) Genome Analysis Used In Research Trial on the Impact of Providing Genetic Risk Assessments
Date:4/8/2008

Compass is the only personal genetic risk assessment to provide on-staff Certified Genetic Counselors to help people understand their individual results.

"The science that links genes with many common inherited diseases is well- established and growing," said Navigenics co-founder and clinical advisory board chair David Agus, M.D. "Now we need to better understand how individuals use this information. Navigenics hopes to learn more about patients' hopes and expectations regarding genetic risk assessment. Our goal is to leverage the wealth of information that genetics can provide to better motivate patients to take action that will improve their health. Our research collaboration with the Mayo Clinic helps us get there."

About Navigenics

Navigenics, Inc. is a privately held company based in Redwood Shores, Calif. The company was founded by David Agus, M.D. and Dietrich Stephan, Ph.D., with the goal of improving health outcomes in individuals across the population. Navigenics educates and empowers customers with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact. Navigenics' lead investors are Kleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr Davidow Ventures. More information is available at http://www.navigenics.com.

FOR MORE INFORMATION:

Hal Mackins

Feinstein Kean Healthcare

Hal.mackins@fkhealth.com

(415) 677-2747

(415) 994-0040 - mobile

Brenna Sweeney

Navigenics

bsweeney@navigenics.com

(206) 999-4796


'/>"/>
SOURCE Navigenics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
2. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
3. Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C
4. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
5. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
6. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
7. Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)
8. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BUENA, N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE ... and manufacturing company, announced its financial results for the second ... Highlights , Total revenues of $6.5 million in ... the same quarter in 2013 , Total revenues of ... an increase of 78% over the same period in 2013 ...
(Date:7/24/2014)... , July 24, 2014  Alimera Sciences, Inc. ... that specializes in the research, development and commercialization of ... its second quarter of fiscal year 2014 financial results ... An investor conference call will follow on the same ... conference call will be hosted by Dan Myers ...
(Date:7/24/2014)...  Kinex Pharmaceuticals announced the receipt of an allowance ... for the commencement of a Phase I clinical study ... to be allowed by the US FDA in the ... orally active and highly selective inhibitor of Src tyrosine ... of p53, G2/M arrest of proliferating cell populations and ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... 5 Diplomat Specialty Pharmacy,announced today that their ... is now live and being utilized to manage,their ... eNAV(TM) as a,disease management tool for all disease ... Crohn,s Disease,and Chronic Kidney Disease., "Our current ...
... of Insulin Doses Administered Were Delivered Within Pre-Determined ... Guidelines and Standard Dosing Limitations, ... the dose accuracy of the SoloSTAR(R) disposable insulin pen,prefilled ... glulisine [rDNA origin] injection), found the pens,accurately delivered all ...
Cached Medicine Technology:Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System 2New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen 2
(Date:7/25/2014)... Agoura Hills dentist , Dr. Amir Choroomi, is ... is one of the most powerful whitening treatments available today, ... light-assisted treatment uses a prescription-strength gel that can penetrate quickly ... up stains that are in both the enamel and the ... and tobacco stains. , About Dr. Amir Choroomi, Expert ...
(Date:7/25/2014)... Health Advocate™, Inc., the nation’s leading ... West Corporation, is introducing its newest solution in an ... Enhance Quality. , The webinar will be held twice ... again at 2 PM ET. For more information or ... or call 866.799.2655. , In an environment of ...
(Date:7/25/2014)... quickly after Manchester research , Clinical judgement, combined ... arrival, is effective in reducing unnecessary hospital admissions ... findings of a research group in Manchester, published ... a huge difference to a large number of ... for emergency hospital admission. In Manchester, the incidence ...
(Date:7/25/2014)... prevents obesity could be on the horizon. Bacteria ... inhibit weight gain, insulin resistance and other adverse ... University investigators have discovered. , "Of course it,s ... senior investigator Sean Davies, Ph.D., assistant professor of ... negative consequences of obesity in mice, even though ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... JDRF’s revenue and spending during fiscal year 2013 (July 1, ... National Institutes of Health (NIH), the JDRF is the largest ... It has global reach and relationships with most of ... positioned to deliver a cure for type 1 diabetes in ...
Breaking Medicine News(10 mins):Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Vanderbilt study examines bacteria's ability to fight obesity 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2
... to GSVM medical college in Kanpur remained affected today ... elite educational institutions entered the 11th day here. // ... the protest against Centre's decision to implement 27 per ... representatives of agitating doctors said., ,However, sources at ...
... a good way of relieving stress and providing the mind ... that exercise can lift a person's spirits// , and there ... clinical depression. Exercise helps in the reduction of anger, fatigue ... walking or running has become popular among health freaks. It ...
... some researchers found that milk chocolate containing caffeine has ... having better reaction times. ,Hence, chocolate ... others. ,Adding value to the above study, ... Professer, Dr. Bryan Raudenbush, Wheeling Jesuit University has done ...
... regulate breathing abnormalities of premature babies. Artificial breathing equipments ... with caffeine therapy and found to have a lower incidence ... , ,About 2,000 premature babies, who weighed below 1,250 grams, ... were studied. , ,More than 47 per ...
... direct talks with Prime Minister Manmohan Singh and decided to ... meeting with the medicos during which he told them that ... which would see a huge growth in the educational opportunities ... Prime Minister assured the medicos that they need not be ...
... A research conducted by the King’s Collage London, analysed health reports ... war in 2003 with those who took part// in the 1991 ... ,The study findings that are published in The Lancet ... War Syndrome" in British male armed forces personnel deployed to the ...
Cached Medicine News:
... non-adhesive sealing method maintains the ... (HALS) procedures, allowing the surgeon ... throughout. Because HALS requires incisions ... patients experience less trauma compared ...
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
... The SleepStyle 200 series offers ... integrated CPAP models. The design delivers ... patients. Performance features promote results in ... care. The strongest differentiator in the ...
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
Medicine Products: